GOT2 and hepatocellular carcinoma: METTL14 may inhibit HCC progression by altering the m6A modification of cysteine sulfonic acid deacidiase (CSAD), glutamic-oxaloacetic transaminase 2 (GOT2) and SOCS2 (109).